A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections | Zendy

Eileen M. Bulger | Zendy; Ronald V. Maier | Zendy; Jason L. Sperry | Zendy; Manjari Joshi | Zendy; Sharon Henry | Zendy; Frederick A. Moore | Zendy; Lyle L. Moldawer | Zendy; Δημήτριος Δημητριάδης | Zendy; Peep Talving | Zendy; Martin A. Schreiber | Zendy; Bruce Ham | Zendy; Mitchell J. Cohen | Zendy; Steven M. Opal | Zendy; Irit Segalovich | Zendy; Greg Maislin | Zendy; Raymond Kaempfer | Zendy; Anat Shirvan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections

Author(s) -

Eileen M. Bulger,

Ronald V. Maier,

Jason L. Sperry,

Manjari Joshi,

Sharon Henry,

Frederick A. Moore,

Lyle L. Moldawer,

Δημήτριος Δημητριάδης,

Peep Talving,

Martin A. Schreiber,

Bruce Ham,

Mitchell J. Cohen,

Steven M. Opal,

Irit Segalovich,

Greg Maislin,

Raymond Kaempfer,

Anat Shirvan

Publication year - 2014

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2013.4841

Subject(s) - medicine , placebo , sepsis , incidence (geometry) , intensive care unit , surgery , randomized controlled trial , clinical endpoint , adverse effect , sofa score , septic shock , pathology , physics , alternative medicine , optics

Necrotizing soft-tissue infections (NSTI) have high morbidity and mortality rates despite aggressive surgical debridement and antibiotic therapy. AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28. We hypothesized that AB103 will limit inflammatory responses to bacterial toxins and decrease the incidence of organ failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research